Apology and Disclosure Conference
A June 6-7 conference, Seeing Your Way Clear to Apology and Disclosure, sponsored by Joint Commission Resources (JCR), will examine how hospitals and healthcare providers can communicate more openly in ways that will ultimately improve patient safety. Two prominent advocates for apology and disclosure—Lucian Leape of the Harvard School of Public Health and Healing Words: The Power of Apology in Medicine author Michael S. Woods—will explore practical strategies to accomplish the difficult task of disclosing and apologizing for errors.
The conference will be held at the Crowne Plaza Chicago O’Hare Hotel, Rosemont, Illinois. For a complete conference agenda and more information, visit http://www.jcrinc.com.
Expanding Recovery Program
The National Alliance on Mental Illness (NAMI) will significantly expand its support group program for people with mental illnesses to all 50 states and Puerto Rico by 2009, thanks to an exclusive multiyear partnership with AstraZeneca, LP. NAMI C.A.R.E. (Consumers Advocating Recovery through Empowerment) is a recovery model in which individuals with serious mental illnesses share experiences in safe, confidential environments and learn coping skills. The expansion aims to have a support group in every major city nationwide, in English and Spanish, with standard training and materials.
Drug Testing Guide
Bill Judge presents “What DOT Supervisors Need to Know About Reasonable Suspicion Testing” for drug/alcohol use. The training kit includes a Leader's Guide binder with reproducible forms and checklists, Something More than a Hunch video/DVD, You Make the Call! video/DVD, DOT Supervisor's Reasonable Suspicion Manual, Do It Right! Reasonable Suspicion and Post Accident Pocket Guide, and an optional DOT DATA CD with rules and digital forms. For more information, visit http://www.buckleyproductions.com.
Guidance on Restraints
ECRI, an independent, nonprofit health services research and patient safety agency, has issued Restraints, a new report from its risk management analysts. Restraints recommends development of a restraint-reduction policy and discusses alternatives, such as using one-to-one sitter programs and tactics to refocus the attention of patients who display at-risk behavior. The report, which also addresses federal and accreditation requirements, offers advice on appropriate use of physical and chemical restraints. To purchase Restraints, contact Sharon Murphy at email@example.com or (610) 825-6000, ext. 5145.
NAADAC Annual Conference
Journey Together is the theme of this year's annual conference of NAADAC, The Association for Addiction Professionals, to be held September 5-8 in Nashville. Cosponsors of this year's conference are the Tennessee Association of Alcoholism & Drug Abuse Counselors and the National Association of Lesbian and Gay Addiction Professionals. Workshop presentations at this year's meeting will address areas such as treatment skills, prevention, adolescents, specialty populations, workplace issues, criminal justice, and workforce development. Early-bird registration rates of $300 for NAADAC members and $375 for nonmembers are in effect until May 6. For more information, visit http://www.naadac.org.
Survey Preparation Software
Standards Manager™ is a new software tool to help providers build a comprehensive package of data and evidence to support conformance to CARF standards. A separate Standards Manager is available for each of the 2007 CARF standards manuals, including Behavioral Health, Child and Youth Services, Employment and Community Services, One-Stop Career Center, and Opioid Treatment Program.
Created by Morning Sun Software Development Corp., Standards Manager can be updated as revised editions of the CARF standards manuals are released each year. The updates allow providers to readily see changes or additions to the standards and help in assessing their ongoing conformance to CARF standards between surveys. For more information, visit http://bookstore.carf.org and click on the Standards Manager link.
New ADHD Treatment
Shire, plc, and its collaborative partner New River Pharmaceuticals, Inc., have announced that the FDA has granted marketing approval for Vyvanse (lisdexamfetamine dimesylate) for the treatment of ADHD. Vyvanse, therapeutically inactive until metabolized in the body, is designed to provide a lower potential for abuse. Vyvanse is expected to be available in the second quarter in three dosage strengths: 30 mg, 50 mg, and 70 mg, all indicated for once-daily dosing. Additional information about Vyvanse is available at http://www.shireadhdtreatments.com.